Covid-19 roundup: Re­searchers claim tri­al suc­cess for Roche's Actem­ra as Alex­ion jumps in; Pfiz­er gam­bling $500M on an am­bi­tious cam­paign

Af­ter Re­gen­eron an­nounced a set­back on Mon­day with its re­search on the use of Kevzara in fight­ing the pan­dem­ic, hopes for the an­ti-in­flam­ma­to­ry IL-6 class waned con­sid­er­ably. But now a group of re­searchers in France are cheer­ing on a win in a con­trolled, ran­dom­ized study of Roche’s ri­val Actem­ra, which has the same mode of ac­tion. And Roche cit­ed it as part of the case for this drug as they push through their own Phase III.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.